Bangkok, Thailand, 12 December, 2024 – DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, has entered a new strategic partnership with MSD (Thailand) Ltd., the local subsidiary of a global research-intensive biopharmaceutical company. Through this collaboration, DKSH will support the commercialization of human papillomavirus (HPV) vaccines in Thailand. The partnership aims to expand market coverage and improve access to preventive healthcare for Thai patients.
This partnership marks another step forward in increasing awareness and vaccination rates for HPV in Thailand, a market that continues to face challenges in preventive care uptake.1 According to a study on “Policy and plan for vaccine production and development in Thailand: a narrative review”, the country faces challenges in ensuring adequate vaccine availability for Thai citizens, particularly during health crises and epidemics. This hampers efforts to achieve health equity and improve outcomes for vulnerable populations.
Under this agreement, DKSH will provide comprehensive Contract Sales Organization (CSO) services and patient solutions ensuring more convenient patient access to the HPV vaccine through hospitals, clinics, and health care partners throughout Thailand.
“By partnering with DKSH, we will be able to further improve healthcare consumers’ access to our vaccines, ultimately improving vaccine coverage rates,” said Dr. Mary Srethapakdi, Managing Director, MSD Thailand. “DKSH’s one hundred year presence in Thailand and their unique go-to market model gives MSD full confidence in this partnership.”
“Partnering with MSD, a globally recognized leader in medicines and vaccines, enables us to deepen our commitment to improving access and delivery of vaccines through innovative and integrated solutions to healthcare consumers,” said Patrik Grande, Vice President, Regional Head of Commercial Outsourcing APAC Healthcare, DKSH. “This collaboration brings our mission to life. With our proven expertise in developing brands with tailored go-to-market strategies, along with our extensive local network, we aim to provide greater access to MSD’s HPV vaccine.”
This partnership with MSD strengthens DKSH’s commitment to addressing critical public health needs in Thailand. As a trusted healthcare partner, DKSH ensures that innovative solutions reach the people who need them most, contributing to a healthier future for Thai communities.
1 Jumlongnark, W. (2023). Policy and plan for vaccine production and development in Thailand: narrative review. Journal of Public Health and Emergency.
(TH-GSL-00569 06/12)
